Constantine (“Dino”) Koutsoubas is a senior associate in the firm’s Chicago office. He focuses his practice on representing generic pharmaceutical companies in Hatch-Waxman patent infringement litigation.

Prior to joining Kelley Drye, Dino was an associate in the patent litigation group at of a major Chicago-based firm where he represented both plaintiffs and defendants at both the trial and appellate level. Since joining Kelley Drye, Dino has focused his practice on helping generic pharmaceutical manufacturers in their efforts to bring their products to market. In this role, he helps clients in every aspect of the Hatch-Waxman process from drafting the initial Paragraph IV notice letter to trial. 

Prior to law school, Dino held a process engineering/research pharmacist role at a major pharmaceutical company. There, he was responsible for scaling up solid dosage form formulations from the clinical scale to the commercial scale validation batches. In that role, he learned each unit operation involved in making tablets, capsules, and soft gels. For his products, he was ultimately responsible for preparing the process development reports for the New Drug Application.

Hatch-Waxman Matters

Merck Sharp & Dohm Corp. et al.  v. Mylan Pharms., Inc., 09–6383 & 10–3085 (JLL) (MAH) (D.N.J.) (ezetimibe & ezetimibe/simvastatin)

Schering Corp v. Glenmark Pharms. Inc., USA, 07–1334 (JLL) (ES) (D.N.J.) (ezetimibe)

Orexo AB v. Mylan Pharms. Inc., 11–3788 (FLW) (LHG) (D.N.J.) (zolpidem tartrate sublingual tablets)

Spectrum Pharms., Inc. et al. v. InnoPharma, Inc. et al., 12–260 (RGA) (CJB) (D. Del.) (levoleucovorin injection)

AstraZeneca Pharms. LP et al. v. Lupin Limited et al., 12–6888 (JAP) (TJB) (D.N.J.) (quetiapine fumarate extended release tablets)

Forest Labs., LLC v. Lupin Limited et al., 14–1058 (D. Del.) (memantine HCl extended release capsules)

UCB Inc. v. CorePharma, LLC, 14–01788 (RMB) (KMW) (D.N.J.) (methylphenidate HCl extended release capsules)

Shire LLC v. CorePharma, LLC, 14–05694 (RMB) (JS) (D.N.J.) (mixed amphetamine salts extended release capsules)

Otsuka Pharm. Co., Ltd. v. Lupin Limited et al., 14–7105 (JBS) (KMW) (D.N.J.) (aripiprazole tablets)

Endo Pharms. Solutions Inc. et al. v. Paddock Laboratories, LLC et al., No. 14–01422 (D. Del.) (SLR) (testosterone undecanoate injection).

Kowa Co. Ltd. et al. v. Lupin Limited et al., 15–3935 (PAC) (S.D.N.Y.) (pitavastatin calcium tablets)

AstraZeneca AB e al. v. Lupin Limited et al.,15–6092 (MLC) (TJB) (D.N.J.) (esomeprazole magnesium delayed-release capsules)

Vanda Pharms. Inc. v. Inventia Healthcare Pvt. Ltd., 15–362 (GMS), 15–921 (GMS) (D. Del.) (iloperidone tablets)

Fresenius Kabi USA, LLC et al. v. Mylan Laboratories Limited et al., 15–942 (LPS) (D. Del.) (ropivacaine HCl injection)


Other Patent Cases

Alma Lasers, Ltd. v. Thermage, Inc., No. 07–224 (GMS) (D. Del.) (cosmetic lasers)

ArcelorMittal v. AK Steel et al., No. 2011–1638 (Fed. Cir.) (cold rolled steel)

BorgWarner Inc. et al v. Hilite Int’l, Inc. et al., No. 07–3339 (N.D. Ill.) (variable camshaft timing)

Hochstein v. Microsoft Corp., No. 04–73071 (PDB) (DAS) (E.D. Mich.), No. 2010–1551 (Fed. Cir.) (video game console)

Hudson Surgical Design, Inc. v. DePuy Orthopaedics, Inc., No. 10–463 (JD) (CAN) (N.D. Ind.) (knee implant technology)

Hydronics, Inc. v. Pfizer, Inc.,AAA Case No. 54 193 Y 00936 08 (animal vaccine)

Lineage Power Corp. v. SynQor Inc., No. 08–0095 (TJW) (CE) (E.D. Tex.) (power converters)

Prestone Products Corp. v. South/Win, Ltd., No. 13–1853 (N.D. Ill.)

Dino was selected as one of Illinois Super Lawyers—Rising Stars, 2015-2017.

Hellenic Bar Association, director &and Judicial Evaluation Committee member

Rehabilitation Institute of Chicago, associate board